BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

Genexine's joint venture in Indonesia allowed to use immunotherapeutic drug in ASEAN and elsewhere

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : Febuary 18, 2021, 15:14 | Updated : Febuary 18, 2021, 15:14
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Genexine]

SEOUL -- Along with technology transfer, a joint venture of Indonesian pharmaceutical group Kalbe Farma and Genexine, a clinical-stage biotechnology company in South Korea, has been granted the right to use GX-I7, an immunotherapeutic drug candidate, in ASEAN, the Middle East, Australia and New Zealand.

GX-I7 is in second-stage clinical trials to confirm o see if it is effective in the treatment of COVID-19. Genexine has said that GX-I7 showed good efficacy when used in combination with a variety of immunotherapeutic agents. Once proven to be effective, KG Bio will apply for emergency use authorization.

Genexine will receive $27 million in down payment as well as milestone payments, which are paid when each milestone is achieved in clinical trials and commercialization, and 10 percent of sales paid separately as royalties. The company will conduct a pre-clinical test to confirm the toxicity of GX-I7 by spraying it to the nasal cavity. 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Genexine works with domestic partners to use cloned pigs for xenotransplantation.
    Genexine works with domestic partners to use cloned pigs for…
  • .Genexine to test toxicity of immunotherapeutic drug candidate for intranasal administration.
    Genexine to test toxicity of immunotherapeutic drug candidat…
  • .Genexine works with domestic company to develop antibody treatment.
    Genexine works with domestic company to develop antibody tre…
  • .Genexines DNA vaccine candidate selected to get quick state support .
    Genexine's DNA vaccine candidate selected to get quick state…

Real Time Photo News

  • .KT jumps into Vietnams music streaming market with digital platform.

    KT jumps into Vietnam's music streaming market with digital platform

  • .K-pop girl band MAMAMOOs label acquires rival entertainment company.

    K-pop girl band MAMAMOO's label acquires rival entertainment company

  • .BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings.

    BTS agency expands U.S. business scope thru acquisition of Ithaca Holdings

  • .CJs drama-making wing forges partnership with webcomics studio YLAB.

    CJ's drama-making wing forges partnership with webcomics studio YLAB

  • .Historical inaccuracies lead to rare withdrawal of TV series in S. Korea.

    Historical inaccuracies lead to rare withdrawal of TV series in S. Korea

Latest News

more+

  • [FOCUS] President Moon hails rollout of home-made fighter jet as 'historic milestone'
  • Researchers develop tiny wearable metasurface gas sensor for holographic visual alarms
  • Researchers discover method to mass-produce carminic acid from glucose
  • KT jumps into Vietnam's music streaming market with digital platform
  • Daewoo shipyard gets smarter with advanced digital technologies
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view